Results 91 to 100 of about 124,717 (304)

Peroxidasin enables melanoma immune escape by inhibiting natural killer cell cytotoxicity

Molecular Oncology, EarlyView.
Peroxidasin (PXDN) is secreted by melanoma cells and binds the NK cell receptor NKG2D, thereby suppressing NK cell activation and cytotoxicity. PXDN depletion restores NKG2D signaling and enables effective NK cell–mediated melanoma killing. These findings identify PXDN as a previously unrecognized immune evasion factor and a potential target to improve
Hsu‐Min Sung, David Bickel, Lena C. M. Krause, Daria Ezeriņa, Christian Ickes, Julian Wojtachnia, Christine S. Gibhardt, Magdalena Shumanska, Khadija Wahni, Andrea Paluschkiwitz, Julia Malo Pueyo, Ekaterina Baranova, Wim Vranken, Hedwig Stanisz, Ioana Stejerean‐Todoran, Michael P. Schön, Joris Messens, Ivan Bogeski   +17 more
wiley   +1 more source

A Phase II Basket Trial of Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors (DART SWOG 1609) in Patients with Nonpancreatic Neuroendocrine Tumors. [PDF]

, 2020
PurposeImmune checkpoint blockade has improved outcomes across tumor types; little is known about the efficacy of these agents in rare tumors. We report the results of the (nonpancreatic) neuroendocrine neoplasm cohort of SWOG S1609 dual anti-CTLA-4 and ...
Baghdadi, Tareq Al, Blanke, Charles D, Chae, Young Kwang, Chen, Helen X, Fontaine, Annette, Gatalica, Zoran, Giles, Francis J, Hansel, Donna E, Hayward, Jourdain, Kasi, Anup, Korn, W Michael, Kurzrock, Razelle, Matrana, Marc, Mayerson, Edward, McLeod, Christine, Othus, Megan, Patel, Sandip P, Plets, Melissa, Ryan, Christopher W, Shah, Manisha H, Sharon, Elad, Singh, Preet Paul   +21 more
core  

Immunotherapy in hepatocellular carcinoma: the complex interface between inflammation, fibrosis, and the immune response. [PDF]

, 2019
Hepatocellular carcinoma (HCC) is the third leading cause of cancer deaths worldwide and confers a poor prognosis. Beyond standard systemic therapy with multikinase inhibitors, recent studies demonstrate the potential for robust and durable responses ...
Fong, Lawrence, Keenan, Bridget P, Kelley, Robin K   +2 more
core   +2 more sources

Combining antibody conjugates with cytotoxic and immune‐stimulating payloads maximizes anti‐cancer activity

Molecular Oncology, EarlyView.
Methods to improve antibody–drug conjugate (ADC) treatment durability in cancer therapy are needed. We utilized ADCs and immune‐stimulating antibody conjugates (ISACs), which are made from two non‐competitive antibodies, to enhance the entry of toxic payloads into cancer cells and deliver immunostimulatory agents into immune cells.
Tiexin Wang, Dong Jun Koo, Peter M. Tessier, Greg M. Thurber   +3 more
wiley   +1 more source

Immune Checkpoint Blockade in Cancer Treatment: A Double-Edged Sword Cross-Targeting the Host as an “Innocent Bystander”

Toxins, 2014
Targeted immune checkpoint blockade augments anti-tumor immunity and induces durable responses in patients with melanoma and other solid tumors. It also induces specific “immune-related adverse events” (irAEs).
Lucia Gelao, Carmen Criscitiello, Angela Esposito, Aron Goldhirsch, Giuseppe Curigliano   +4 more
doaj   +1 more source

Mechanisms of Resistance to Immune Checkpoint Blockade [PDF]

American Journal of Clinical Dermatology, 2018
The recent development of effective immune checkpoint inhibition (ICI), first demonstrated in melanoma, has revolutionized cancer treatment. Monoclonal antibodies blocking the immune checkpoints cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) and programmed death 1 receptor (PD-1) have shown substantial clinical benefit in a subset of patients ...
David, Liu, Russell W, Jenkins, Ryan J, Sullivan   +2 more
openaire   +2 more sources

Tumor mutational burden as a determinant of metastatic dissemination patterns

Molecular Oncology, EarlyView.
This study performed a comprehensive analysis of genomic data to elucidate whether metastasis in certain organs share genetic characteristics regardless of cancer type. No robust mutational patterns were identified across different metastatic locations and cancer types.
Eduardo Candeal, Andrea Moreno‐Manuel, Miguel Salvadó‐Pertierra, Cristina Santos‐Vivas, Rebeca Sanz‐Pamplona   +4 more
wiley   +1 more source

Bilateral anterior uveitis after immunotherapy for malignant melanoma

Taiwan Journal of Ophthalmology, 2018
Immune checkpoint blockade therapy is relatively a new treatment for cancer which has shown promising results. However, immune-related side effects including uveitis have occasionally been reported during this therapy.
Chia-Jui Chang, Shih-Jen Chen, De-Kuang Hwang, Catherine Jui-Ling Liu   +3 more
doaj   +1 more source

Novel Combination Strategies to Enhance Immune Checkpoint Inhibition in Cancer Immunotherapy: A Narrative Review

International Journal of Medical Students, 2020
Programmed cell death protein-1 (PD-1) is an immune checkpoint receptor that induces and maintains tolerance of T cells, invariant natural killer T (iNKT) cells, and natural killer (NK) cells, among other lymphocytes.
Jonathan A. Hermel, Cassi M. Bruni, Darren S. Sigal   +2 more
doaj   +1 more source

Alterations of immune response of non-small lung cancer with azacytidine [PDF]

, 2013
Innovative therapies are needed for advanced Non-Small Cell Lung Cancer (NSCLC). We have undertaken a genomics based, hypothesis driving, approach to query an emerging potential that epigenetic therapy may sensitize to immune checkpoint therapy targeting
Baylin, Stephen B, Brahmer, Julie R, Brock, Malcolm V, Carvajal, Richard D, De Meyer, Tim, Du, Zhengzong, Easton, Keith, Easwaran, Hariharan, Jones, Peter A, Juergens, Rosalyn A, Koch, Alexander, Laird, Peter W, Mohammad, Helai P, Pardoll, Drew, Parsana, Princy, Rodgers, Kristen, Rudin, Charles M, Taube, Janis M, Topalian, Suzanne L, Tsai, Salina, Tykodi, Scott S, Van Criekinge, Wim, Vendetti, Frank, Wang, Wei, Weisenberger, Daniel J, Wrangle, John, Yen, Ray-Whay, Zahnow, Cynthia A   +27 more
core   +1 more source